Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.

The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and innovation.

Shares Biotechnology ETF earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward.

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

Biotech-based exchange-traded fund (“ETF”) iShares Biotechnology ETF IBB rallied 30.2% over the past six months (as of Oct. 15, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 26.5%). Year to date ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. The ETF industry has long been ...